Grant of Options

RNS Number : 8711V

C4X Discovery Holdings PLC

05 December 2019

 

C4X Discovery Holdings plc

("C4XD" or the "Company")

GRANT OF OPTIONS AND DIRECTORS DEALING

5 December 2019 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, announces today that a total of 750,000 options over ordinary shares of the Company were awarded pursuant to the EMI 2014 Plan to certain employees, which includes 250,000 options each to Dr Clive Dix, Chief Executive Officer, Dr Craig Fox, Chief Scientific Officer and Brad Hoy, Chief Financial Officer, as set out below.

Director	Position	Number of share options awarded	Option exercise price per share (pence)	Total number of options held
Dr Clive Dix	Chief Executive Officer	250,000	16.2	445,000
Dr Craig Fox	Chief Scientific Officer	250,000	16.2	500,000
Brad Hoy	Chief Financial Officer	250,000	16.2	600,000

The options have an exercise price of 16.2p, being the average 5-day VWAP of the Ordinary Shares to the 29 November 2019. The options can be exercised at any time between 3 years and 10 years of them being granted.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

For further information, please contact:

C4X Discovery Holdings plc

Clive Dix, Chief Executive Officer                                                                                                            07801 865 803

Panmure Gordon (UK) Limited (NOMAD)                                                                                          020 7886 2500

Freddy Crossley, Emma Earl (Corporate Finance)                                                                                              

James Stearns (Corporate Broking)                                                                                                                         

Consilium Strategic Communications

Mary-Jane Elliott, Matthew Neal, Chris Gardner                                                                                0203 709 570

About C4X Discovery

C4X Discovery (C4XD) aims to create the world's most productive Drug Discovery engine by using cutting-edge technologies and expertise to efficiently deliver best-in-class small-molecule medicines to clinical partners for the benefit of patients. The Company's business model focuses on replenishing big pharma discovery pipelines and driving returns through revenue generating pre-clinical licensing deals. In 2018, C4XD successfully out-licensed a pre-clinical programme in addictive disorders to Indivior in a deal worth up to $294m.

C4XD has a state-of-the-art suite of proprietary technologies across the Drug Discovery process and accesses further innovative capabilities and expertise through its growing network of partners. The Company is actively advancing its diverse pre-clinical discovery portfolio which is focused on inflammation, neurodegeneration and oncology (including immuno-oncology). Opportunities to maximise value from the portfolio are proactively driven by C4XD's commercial division. The Company is led by a highly experienced management team and Board who have delivered significant value creation within the healthcare sector.

For additional information please go to: www.c4xdiscovery.com 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and/or persons closely associated with them:

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Clive Dix
2	Reason for the notification
a)	Position/status	Chief Executive Officer, Director
b)	Initial notification/Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	C4X Discovery Holdings plc
b)	LEI	213800UHNL82E323O870
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Options over 1p Ordinary Shares - EMI 2014 Plan  ISIN GB00BQQ2RV18
b)	Nature of the transaction	Grant of Options over Ordinary Shares
c)	Price(s) and volume(s)	Price(s) per Ordinary Share Volume(s) 16.2p 250,000
d)	Aggregated information	Price Volume(s) N/A N/A
e)	Date of the transaction	29 November 2019
f)	Place of the transaction	London Stock Exchange - AIM

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Craig Fox
2	Reason for the notification
a)	Position/status	Chief Scientific Officer, Director
b)	Initial notification/Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	C4X Discovery Holdings plc
b)	LEI	213800UHNL82E323O870
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Options over 1p Ordinary Shares - EMI 2014 Plan  ISIN GB00BQQ2RV18
b)	Nature of the transaction	Grant of Options over Ordinary Shares
c)	Price(s) and volume(s)	Price(s) per Ordinary Share Volume(s) 16.2p 250,000
d)	Aggregated information	Price Volume(s) N/A N/A
e)	Date of the transaction	29 November 2019
f)	Place of the transaction	London Stock Exchange - AIM

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Brad Hoy
2	Reason for the notification
a)	Position/status	Chief Financial Officer, Director
b)	Initial notification/Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	C4X Discovery Holdings plc
b)	LEI	213800UHNL82E323O870
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Options over 1p Ordinary Shares - EMI 2014 Plan  ISIN GB00BQQ2RV18
b)	Nature of the transaction	Grant of Options over Ordinary Shares
c)	Price(s) and volume(s)	Price(s) per Ordinary Share Volume(s) 16.2p 250,000
d)	Aggregated information	Price Volume(s) N/A N/A
e)	Date of the transaction	29 November 2019
f)	Place of the transaction	London Stock Exchange - AIM

Name of authorised official of issuer responsible for making notification: Brad Hoy, Chief Financial Officer of the Company.

--ENDS-

 

END

 

 

DSHUVUSRKUAURAA